Marketing-authorisation holder
Deciphera Pharmaceuticals (Netherlands) B.V.
12 medicines in 4 countries, as authorisation holder and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder
12 medicines in 4 countries, as authorisation holder and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
12 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| QINLOCKCompressa | Ripretinib | Italy | Authorised | |
| Qinlock | Ripretinib | EU (EMA) | Authorised | 2021 |
| QINLOCK 50 MG COMPRIMIDOS50 mg · Comprimido | Ripretinib | Spain | Marketed | 2023 |
| Qinlock 50 mg tablettenTablet | Ripretinib | Netherlands | Authorised | 2021 |
| ROMVIMZACapsula rigida | Vimseltinib | Italy | Authorised | |
| Romvimza | Vimseltinib | EU (EMA) | Authorised | 2025 |
| ROMVIMZA 14 MG CAPSULAS DURAS14 mg · Cápsula dura | Vimseltinib | Spain | Authorised | 2025 |
| ROMVIMZA 14 mg harde capsulesCapsule, hard | Vimseltinib | Netherlands | Authorised | 2025 |
| ROMVIMZA 20 MG CAPSULAS DURAS21,68 mg · Cápsula dura | Vimseltinib | Spain | Authorised | 2025 |
| ROMVIMZA 20 mg harde capsulesCapsule, hard | Vimseltinib | Netherlands | Authorised | 2025 |
| ROMVIMZA 30 MG CAPSULAS DURAS30 mg · Cápsula dura | Vimseltinib | Spain | Authorised | 2025 |
| ROMVIMZA 30 mg harde capsulesCapsule, hard | Vimseltinib | Netherlands | Authorised | 2025 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 4 | 4 | 0 | CompaniesAll medicines |
| Netherlands | 4 | 4 | 0 | CompaniesAll medicines |
| European Union (EMA) | 2 | 2 | 0 | CompaniesAll medicines |
| Italy | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.